First-in-human safety, tolerability, and pharmacokinetics of ammoxetine in healthy subjects: a randomized, double-blind, placebo-controlled phase I study

European Journal of Pharmaceutical Sciences ◽

10.1016/j.ejps.2021.105724 ◽

2021 ◽

Vol 159 ◽

pp. 105724

Author(s):

Qi Shen ◽

Chao Hu ◽

Jia Miao ◽

Junxia Chen ◽

Yueying Peng ◽

...

Keyword(s):

Phase I ◽

Healthy Subjects ◽

Phase I Study ◽

Double Blind ◽

Double Blind Placebo ◽

Download Full-text

Randomised, Double-Blind, Placebo-Controlled, Dose-Escalating Phase I Study of QGC001, a Centrally Acting Aminopeptidase A Inhibitor Prodrug

Clinical Pharmacokinetics ◽

10.1007/s40262-013-0125-y ◽

2013 ◽

Vol 53 (4) ◽

pp. 385-395 ◽

Author(s):

Fabrice Balavoine ◽

Michel Azizi ◽

Damien Bergerot ◽

Nadia De Mota ◽

Rémi Patouret ◽

...

Keyword(s):

Phase I ◽

Phase I Study ◽

Double Blind ◽

Double Blind Placebo ◽

Aminopeptidase A ◽

Aminopeptidase A Inhibitor ◽

Dose Escalating

Download Full-text

Pharmacokinetics, Safety, and Tolerability of Intravenous Felbinac Trometamol in Healthy Chinese Volunteers: A First-in-Human Single- and Multiple-Dose Escalation Phase I Study with a Randomized, Double-Blind, Placebo-Controlled Design

CNS Drugs ◽

10.1007/s40263-020-00739-z ◽

2020 ◽

Vol 34 (8) ◽

pp. 867-877

Author(s):

Min Wu ◽

Cuiyun Li ◽

Hong Zhang ◽

Jixuan Sun ◽

Xiaoxue Zhu ◽

...

Keyword(s):

Phase I ◽

Dose Escalation ◽

Phase I Study ◽

Multiple Dose ◽

Double Blind ◽

Double Blind Placebo ◽

Healthy Chinese

Download Full-text

Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase I, Healthy Subjects Study of Intravenous OPN-305, a Humanized Anti-TLR2 Antibody

Clinical Pharmacology & Therapeutics ◽

10.1038/clpt.2013.150 ◽

2013 ◽

Vol 94 (5) ◽

pp. 593-600 ◽

Author(s):

M Reilly ◽

R M Miller ◽

M H Thomson ◽

V Patris ◽

P Ryle ◽

...

Keyword(s):

Phase I ◽

Healthy Subjects ◽

Double Blind ◽

Double Blind Placebo ◽

Dose Escalating

Download Full-text

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects

CNS Drugs ◽

10.1007/s40263-018-0578-5 ◽

2018 ◽

Vol 32 (11) ◽

pp. 1053-1067 ◽

Author(s):

Lesley Taylor ◽

Barry Gidal ◽

Graham Blakey ◽

Bola Tayo ◽

Gilmour Morrison

Keyword(s):

Phase I ◽

Healthy Subjects ◽

Multiple Dose ◽

Food Effect ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

A Phase I, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Naloxegol on Gastric, Small Bowel, and Colonic Transit in Healthy Subjects Receiving Codeine or Placebo: 2017 Fellows-in-Training Award (Functional Bowel Disease Category) 2017 Presidential Poster Award

The American Journal of Gastroenterology ◽

10.14309/00000434-201710001-00431 ◽

2017 ◽

Vol 112 ◽

pp. S230 ◽

Author(s):

Houssam Halawi ◽

Priya Vijayvargiya ◽

Irene Busciglio ◽

Ibironke Oduyebo ◽

Disha Khemani ◽

...

Keyword(s):

Small Bowel ◽

Phase I ◽

Bowel Disease ◽

Healthy Subjects ◽

Colonic Transit ◽

Controlled Study ◽

Disease Category ◽

Double Blind ◽

Double Blind Placebo ◽

Download Full-text

NXY-059 Does Not Affect Bleeding Time in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled, 3-Period Crossover Phase I Study

The Journal of Clinical Pharmacology ◽

10.1177/0091270006293752 ◽

2007 ◽

Vol 47 (2) ◽

pp. 264-272 ◽

Author(s):

Dag Nilsson ◽

Johan Wemer ◽

Yi-Fang Cheng ◽

Ingalill Reinholdsson ◽

Gunnar Englund ◽

...

Keyword(s):

Phase I ◽

Healthy Volunteers ◽

Phase I Study ◽

Bleeding Time ◽

Double Blind ◽

Double Blind Placebo ◽

Crossover Phase

Download Full-text

(420) NEO6860, a novel modality selective TRPV1 antagonist: results from a phase I, double-blind, placebo-controlled study in healthy subjects

Journal of Pain ◽

10.1016/j.jpain.2016.01.397 ◽

2016 ◽

Vol 17 (4) ◽

pp. S79 ◽

Author(s):

D. Chiche ◽

W. Brown ◽

P. Walker

Keyword(s):

Phase I ◽

Healthy Subjects ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Trpv1 Antagonist

Download Full-text

Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: A dose—block-randomized, double-blind, placebo-controlled, ascending single-dose, phase I study

Clinical Therapeutics ◽

10.1016/j.clinthera.2008.10.013 ◽

2008 ◽

Vol 30 (10) ◽

pp. 1817-1830 ◽

Author(s):

Kyoung Soo Lim ◽

Jung-Ryul Kim ◽

Yun-Jung Choi ◽

Kwang-Hee Shin ◽

Kyu-Pyo Kim ◽

...

Keyword(s):

Single Dose ◽

Phase I ◽

Phase I Study ◽

Dipeptidyl Peptidase ◽

Dipeptidyl Peptidase Iv ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Safety profile of the SQ house dust mite sublingual immunotherapy-tablet in Japanese adult patients with house dust mite-induced allergic asthma: a randomized, double-blind, placebo-controlled phase I study

Journal of Asthma ◽

10.1080/02770903.2018.1541353 ◽

2018 ◽

Vol 56 (12) ◽

pp. 1347-1355 ◽

Author(s):

Kazuhiro Okamiya ◽

Hisakuni Sekino ◽

Ryuji Azuma ◽

Minoru Kudo ◽

Miyuki Sakaguchi ◽

...

Keyword(s):

Phase I ◽

House Dust Mite ◽

Safety Profile ◽

Phase I Study ◽

Sublingual Immunotherapy ◽

Japanese Adult ◽

Double Blind ◽

Double Blind Placebo ◽

Download Full-text

Sa1767 - Eb8018, a Novel Fimh Blocker is well Tolerated in a Randomized, Double-Blind, Placebo -Controlled Phase I Study in Healthy Volunteers

Gastroenterology ◽

10.1016/s0016-5085(18)31591-9 ◽

2018 ◽

Vol 154 (6) ◽

pp. S-387

Author(s):

Jaikrishna Patel ◽

Jean-Michel Paillarse ◽

Patricia Françon ◽

Arnaud Laveissière ◽

Christophe Bonny ◽

...

Keyword(s):

Phase I ◽

Healthy Volunteers ◽

Phase I Study ◽

Double Blind ◽

Double Blind Placebo

Download Full-text